Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
LABTNASDAQ

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc.
Loading price data…
Loading price data…
Chart type
Interval
Moving averages
Up/down colors

Share screenshot

Recent & upcoming events

Nov 10
Est.
Lock-up Time TBD
IPO lock-up expiry (est., 180d)
Add to Google Calendar
Dec 30
Est.
IPO 7:00
New listing (scheduled)
Add to Google Calendar

KPI highlights

FY25
Revenue $0 YoY —
Operating income $-4M
Net income $-4M YoY —
EPS $-0.28 YoY —
P/E —
ROE 195.9% Sign disagrees with net income (may reflect a one-time accounting item)

Quarterly fundamentals

Income & cash flow Unit: $1M
Quarter FY24 Q3FY24 Q4FY25 Q1FY25 Q3FY25 Q4FY26 Q1
Revenue 0.000.000.000.000.000.00
Operating income -0.91-0.86-0.54-1.88-0.71-0.89
Net income -1.94-0.85-0.54-1.91-0.74-0.92
Operating CF ——-0.44—-0.59-0.71

Company news

F-Score (Piotroski)

1/7 3 of 7 items lack data

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

ROE and related signals above include a period where the sign disagrees with net income due to a one-time accounting item (see the ROE note in the KPI highlights above).

— Positive ROAExcluded from this period due to the net income/ROE sign mismatch N/A
✗ Positive operating cash flow $-2M
— ROA improved YoYExcluded from this period due to the net income/ROE sign mismatch N/A
✓ Operating CF exceeds net income (accrual quality) OCF $-2M / net income $-4M
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 38.3% → -407.9%
— Current ratio improved No data
— No dilution (shares outstanding did not increase) No data
— Gross margin improved No data
✗ Asset turnover improved 0.00× → 0.00×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY25
Equity ratio -407.9%
Current ratio —
Years of positive operating CF 0 of last 2 yrs
Payout ratio 0%
Latest fiscal year result Loss (net loss $4M)

Performance history

Last 10 years
$0K$0K$0K$0K$0K FY24FY25

Income & assets

Unit: $1M
Item FY24FY25
Revenue 0.000.00
Operating income -4.03-3.77
Ordinary income ——
Net income -4.86-3.85
Total assets 1.070.48
Equity 0.41-1.96

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Indicators & cash flow

Unit: $1M
Item FY24FY25
EPS $-0.35$-0.28
ROE -1185.4%195.9%
Operating CF -4.91-2.27
Investing CF 3.920.00
Financing CF -0.051.50
FCF -5.73-1.94

Source: Twelve Data (fetched 2026-06-16) *Some metrics supplemented from additional sources

Key financial metrics

High ROE ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data